Regulus Therapeutics

Type: Company
Name: Regulus Therapeutics
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Regulus Therapeutics major shareholder Unloads $15,795 in Stock (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) major shareholder Alnylam Pharmaceuticals, Inc. sold 2,250 shares of Regulus Therapeutics stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $7.02, for a total transaction ... [Published American Banking News - Forex - Aug 16 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

REGULUS THERAPEUTICS : Reports Second Quarter 2014 Financial Results and Recent Highlights

By a News Reporter-Staff News Editor at Biotech Week -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, reported financial results and highlights for ... [Published 4 Traders - Aug 13 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 2 reports

Regulus to Speak at Wedbush Life Sciences Management Access Conference

Regulus Therapeutics' Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Wedbush Life Sciences Management Access Conference on Wednesday, August 13, at 9:45 a.m. EDT. According to the company, the conference ... [Published Individual.com - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Regulus Therapeutics Receives Average Recommendation of “Buy” from Brokerages (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS) has received an average rating of "Buy" from the nine analysts that are currently covering the company, . One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation ... [Published American Banking News - Aug 12 2014]
First reported Aug 09 2014 - Updated Aug 09 2014 - 1 reports

Insider Selling: Regulus Therapeutics Director Sells 1,850 Shares of Stock (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc unloaded 1,850 shares of Regulus Therapeutics stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $6.80, for a total value of $12,580.00. The sale ... [Published American Banking News - Forex - Aug 09 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Regulus Therapeutics Given Average Recommendation of “Buy” by Analysts (NASDAQ:RGLS)

Shares of Regulus Therapeutics (NASDAQ:RGLS) have been given an average rating of “Buy” by the nine ratings firms that are currently covering the stock, AmericanBankingNews.com reports. One investment analyst has rated the stock with a sell recommendation ... [Published American Banking News - Forex - Aug 08 2014]
First reported Aug 06 2014 - Updated Aug 07 2014 - 5 reports

Regulus to Present at the Wedbush Life Sciences Management Access Conference

LA JOLLA, Calif., Aug. 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., ... [Published TickerTech.com - Aug 07 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Regulus Therapeutics misses by $0.10, misses on revenue

17:11 ET | About: Regulus Therapeutics (RGLS)Regulus Therapeutics (NASDAQ:RGLS): Q2 EPS of -$0.29 misses by $0.10.Revenue of $0.7M (-85.3% Y/Y) misses by $2.49M. ... [Published Seeking Alpha - Aug 06 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 3 reports

Regulus Therapeutics, Inc. Enters Into New Collaboration Agreement With Biogen Idec, Inc. (California) To Identify Microrna Biomarkers In Multiple Sclerosis

Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: NEXT ARTICLE More From BioPortfolio on "Regulus Therapeutics, Inc. Enters Into New Collaboration Agreement With Biogen Idec, Inc. (California) To Identify Microrna Biomarkers ... [Published BioPortfolio - Aug 05 2014]
First reported Aug 02 2014 - Updated Aug 02 2014 - 1 reports

Regulus Therapeutics Director Isis Pharmaceuticals Inc Unloads 2,600 Shares (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc sold 2,600 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $6.21, for a total transaction ... [Published American Banking News - Aug 02 2014]
First reported Jul 30 2014 - Updated Jul 31 2014 - 2 reports

Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call

SOURCE Regulus Therapeutics Inc.LA JOLLA, Calif.Regulus will host a conference call and webcast on Wednesday, August 6, 2014About RegulusRegulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative ... [Published 14 WFIE - Jul 30 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Regulus Therapeutics Director Sells $11,135 in Stock (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc sold 1,700 shares of the stock on the open market in a transaction dated Friday, July 25th. The stock was sold at an average price of $6.55, for a total transaction of $11,135.00. The ... [Published American Banking News - Jul 26 2014]

Quotes

...all which support our leadership position in the microRNA therapeutics field," said Kleanthis G Xanthopoulos , Ph D , President and CEO of Regulus. "Recently, we were pleased to report additional progress on the business front with the expansion of our relationship with Biogen Idec to identify microRNA biomarkers for multiple sclerosis. The Regulus microMarkers™ division continues to mature and we hope to leverage our innovative technology platform to further advance our microRNA therapeutic pipeline, our collaborations and partners' programs in a meaningful way."
...panel discussions including: "Ophthalmology Treatments and Tools" hosted by Liana Moussatos, Managing Director and Tao Levy, Managing Director; "Regulatory and Reimbursement Outlook for Medical Devices and Molecular Diagnostics" hosted by Tao Levy, Managing Director; and "Gene Therapies" hosted by David Nierengarten, Managing Director
Regulus Therapeutics chief business officer and general counsel David Szekeres said: "We are pleased to grow the Regulus microMarkers division and expand our research on microRNA biomarkers with Biogen Idec."
...a filing that it will undertake restructuring activities to streamline operationsHasbro (HAS) CEO announced prostate cancer diagnosis, says he will "continue to enthusiastically fulfill all my responsibilities as Hasbro's President and CEO on a full-time basis with no interruption in my tenure" GM (GM) issued recall for certain model year SAABs, Trailblazer EXTs, others; Toyota (TM) recalled 2014 Siennas due to defected transmission shift control...

More Content

All (80) | News (55) | Reports (0) | Blogs (25) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Regulus Therapeutics major shareholder Unloads ... [Published American Banking News - Forex - Aug 16 2014]
Biotech Stock Directory Update [Published InvestorIdeas.com - Aug 14 2014]
REGULUS THERAPEUTICS : Reports Second Quarter 2... [Published 4 Traders - Aug 13 2014]
Alnylam to Host Additional Events in "RNAi Roun... [Published Pharmacy Choice - Aug 13 2014]
Net loss widens for Regulus [Published Seeking Alpha - Aug 12 2014]
Wedbush PacGrow Life Sciences Hosts Management ... [Published Nations Restaurant News - Aug 12 2014]
Regulus Therapeutics Receives Average Recommend... [Published American Banking News - Aug 12 2014]
Regulus to Speak at Wedbush Life Sciences Manag... [Published Individual.com - Aug 12 2014]
Regulus to Present at Wedbush Life Sciences Con... [Published Individual.com - Aug 12 2014]
Regulus Posts 2nd Quarter Financial Results and... [Published Individual.com - Aug 12 2014]
Insider Selling: Isis Pharmaceuticals Inc Sells... [Published American Banking News - Forex - Aug 11 2014]
Insider Selling: Regulus Therapeutics Director ... [Published American Banking News - Forex - Aug 09 2014]
Regulus Therapeutics Given Average Recommendati... [Published American Banking News - Forex - Aug 08 2014]
Regulus to Present at the Wedbush Life Sciences... [Published TickerTech.com - Aug 07 2014]
Regulus to Present at the Wedbush Life Sciences... [Published PR Newswire: Health - Aug 07 2014]
Alnylam Pharmaceuticals Reports Second Quarter ... [Published Wall Street Select - Aug 07 2014]
Regulus and Biogen partner to identify microRNA... [Published Pharmaceutical Technology - Aug 07 2014]
Frontrunning: August 7 [Published Zero Hedge - Aug 07 2014]
Regulus Therapeutics' (RGLS) CEO Kleanthis Xant... [Published Seeking Alpha - Aug 07 2014]
Regulus Reports Q2 Results [Published San Diego Business Journal - Aug 06 2014]
Regulus Therapeutics misses by $0.10, misses on... [Published Seeking Alpha - Aug 06 2014]
Regulus Reports Second Quarter 2014 Financial R... [Published Pettinga Financial Advisors - Aug 06 2014]
Regulus Reports Second Quarter 2014 Financial R... [Published TickerTech.com - Aug 06 2014]
Regulus Reports Second Quarter 2014 Financial R... [Published PR Newswire: Financial Services - Aug 06 2014]
GMED Outlook Spooks Investors, CYTX Trials Plac... [Published RTTNews.com - Aug 06 2014]
Regulus, Biogen in microRNA Biomarker Pact [Published Contract Pharma - Aug 05 2014]
Regulus shares up on deal with Biogen for micro... [Published Pharma Letter - Aug 05 2014]
Regulus Therapeutics, Inc. Enters Into New Coll... [Published BioPortfolio - Aug 05 2014]
Regulus Enters Into New Collaboration Agreement... [Published ADVFN India - Aug 05 2014]
Regulus Enters Into New Collaboration Agreement... [Published PR Newswire: Health - Aug 05 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Regulus to Present at the Wedbush Life Sciences... [Published PR Newswire: Health - Aug 07 2014]
LA JOLLA, Calif., Aug. 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., ...
Frontrunning: August 7 [Published Zero Hedge - Aug 07 2014]
Russia bans all U.S. food, EU fruit and vegetables in sanctions response ( Reuters ) Snowden receives three-year Russian residence permit ( Reuters ) Headline of the day: Europe's Recovery Menaced by Putin as Ukraine Crisis Bites ( BBG ) Americans worry ...
Regulus Reports Second Quarter 2014 Financial R... [Published PR Newswire: Financial Services - Aug 06 2014]
LA JOLLA, Calif., Aug. 6, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for ...
Regulus Enters Into New Collaboration Agreement... [Published PR Newswire: Health - Aug 05 2014]
LA JOLLA, Calif., Aug. 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a new collaboration agreement ...
Biotech CEOs Speak Out on JOBS Act Success [Published I Am Biotech - Jul 31 2014]
Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and ...
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.